Abstract
To the Editor: We read with interest the report by Canonico and colleagues1 that shows a differential association of oral and transdermal estrogen with venous thromboembolism (VTE) risk among postmenopausal women. In addition, their data suggest that norpregnane derivatives may be thrombogenic (with a 4-fold-increased VTE risk), whereas micronized progesterone and pregnane derivatives appear safe with respect to …
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
